Loading clinical trials...
Loading clinical trials...
Prevalence of Depression and Anxiety Symptoms Among Newly Diagnosed Breast Cancer Patients in Almaty, Kazakhstan
Depression and anxiety in patients with breast cancer is serious comorbidity that affects the quality of life for patients, and their survival rates as they have poorer health outcomes. Furthermore, patients' high psychological burden is linked to higher healthcare costs. The investigation of the depression and anxiety symptoms prevalence among newly diagnosed breast cancer patients will help to navigate the health policy adjustment and psycho-social support system requirements. This study aims to investigate the prevalence of depression and anxiety symptoms among newly diagnosed breast cancer patients in Almaty, Kazakhstan, and associated risk factors.
Age
18 - 75 years
Sex
FEMALE
Healthy Volunteers
No
Almaty Oncology Center
Almaty, Kazakhstan
Kazakh Institute of Oncology and Radiology
Almaty, Kazakhstan
Start Date
May 17, 2021
Primary Completion Date
February 21, 2022
Completion Date
March 10, 2022
Last Updated
March 25, 2022
162
ACTUAL participants
Lead Sponsor
Kazakh Medical University of Continuing Education
Collaborators
NCT07360600
NCT05673200
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions